The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial

TL;DR

A clinical trial found that Ganwei, a supplement that boosts GNMT activity, may help reduce liver fat in patients with metabolic dysfunction-associated steatotic liver disease.

Contribution

This study is the first to show that Ganwei improves liver steatosis in MASLD patients, with effects dependent on a specific genetic variant.

Findings

Ganwei alone significantly reduced liver steatosis compared to placebo.

Improvement with Ganwei was only observed in patients with the T allele at GNMT rs10948059.

No serious adverse events were reported in any treatment group.

Abstract

Metabolic dysfunction associated steatotic liver disease (MASLD), a globally prevalent chronic liver disease, has only limited pharmacological options. Both metformin and Ganwei, health supplements containing a potent inducer of glycine N-methyltransferase (GNMT), have shown great promise for the treatment of MASLD. We conducted a 4-arm, randomized, placebo-controlled trial to investigate the safety and efficacy of metformin and Ganwei for patients with MASLD. Between September 2021 and March 2023, 64 patients with MASLD were randomly assigned at a 1:1:1:1 ratio to receive metformin alone (arm A, n = 16), a combination of metformin and Ganwei (arm B, n = 16), a placebo alone (arm C, n = 16) or Ganwei alone (arm D, n = 16) for 6 months. The primary liver steatosis outcome was assessed by control attenuation parameter (CAP) and kilopascal (kPa) scores via FibroScan. The key secondary outcomes included safety, liver function and patients’ metabolic profiles. At 6 months after treatment, significant improvements in liver steatosis were observed in patients treated with Ganwei alone (repeated-measures ANOVA test, p = 0.048 and 0.048 for CAP and kPa scores, respectively) but not in patients treated with placebo and other arms. By employing a 6-point steatosis grade scale, the Ganwei alone arm exhibited a statistically significant improvement over the placebo-controlled arm (mean score 1.1 ± 1.8 vs. 0.1 ± 0.7, p = 0.036). Located in the promoter region of the GNMT gene, the SNP rs10948059 polymorphism is known to affect GNMT promoter activity. Interestingly, genotype analysis revealed that the improvement in liver steatosis in the Ganwei alone arm was restricted to patients harboring the T allele at GNMT rs10948059 (C/T and T/T vs. C/C, p < 0.05). No serious adverse events were observed in any of the treatment arms. Our study demonstrated that Ganwei may be an effective treatment option for MASLD patients. Improvement in liver steatosis by Ganwei was affected by GNMT promotor activity. Clinical trial registration: NCT06244550.

Figures